Structure Therapeutics Inc.
GPCR · Nasdaq · USD · Market cap $1.3B · 220 employees
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price16.13 USD at the 20 Nov 2026 close
- Fair valueUnder review: the analyst targets sit too far from the price to cross-check it; our model's value is 4.34x the price, above our 2.00x limit.
- Our regime readMarkdown, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Structure Therapeutics Inc. holds its Markdown at $16.13. The statistical read favours the sellers, held for 68 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 68 days |
| Price at the screen | $16.13 |
| Valuation | N/A trailing · -7.42 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | -1.20 |
Five Screens: GPCR's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.41% | Below 33% | Pass |
| Interest-bearing cash | 40.82% | Below 33% | Fail |
| Receivables | 56.80% | Below 49% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Structure Therapeutics's business is fine, but its cash and interest-bearing securities are about 41% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when GPCR's ethical verdict changes
Today GPCR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. The analyst targets sit too far from the price to cross-check it; our model's value is 4.34x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 14 covering, consensus Strong Buy. Average target +523%.
Clinical biotech with no profits or data
Imagine handing cash to a lab team that has never turned a profit and cannot show basic financial ratios. Structure Therapeutics is exactly that, a clinical stage player developing oral molecules for chronic disease. The opportunity rating sits at none, the ethical screen returns insufficient data, and with zero profit margin plus negative fifteen percent return on equity the business offers nothing to anchor a position.
Forward earnings sit at a negative twenty five times multiple while the share price of forty eight dollars trades at half the analyst median target. That gap looks tempting only until the complete absence of moat data and financial ratios is factored in. Without those foundations any apparent margin of safety remains an accounting mirage.
Clinical trials can fail at any stage, cash burn is constant, and the ethical gaps alone rule out further work. Analysis, not advice.
| Forward P/E | -7.4x |
| EPS, trailing | -3.90 |
| EPS, forward | -2.50 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -20.2%not currently earning a positive return on equity |
| FCF yield | -8.96% |
| Debt to equity | 0.46minimal debt: a conservative balance sheet |
| Current ratio | 20.75comfortably covers its short-term bills |
| Beta | -1.20barely tracks the market's swings |
| Short interest, float | 0.14% |
| 52-week range | 18.38 - 94.90 |
| Market cap | $1.3B |
| Employees | 220 |
GPCR-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research Yahoo Finance · 9d ago
- Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Yahoo Finance · 12d ago
- Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference Yahoo Finance · 17d ago
- Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026 Yahoo Finance · 19 Oct 2026
- Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base Yahoo Finance · 17 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $38.32 | +7.6% | · | $1,076 | +7.6% |
| 2 months | $54.51 | -24.3% | · | $757 | -24.3% |
| 3 months | $54.58 | -24.4% | · | $756 | -24.4% |
| 6 months | $67.44 | -38.9% | · | $612 | -38.9% |
| 1 year | $21.83 | +88.9% | · | $1,889 | +88.9% |
| 2 years | $52.91 | -22.1% | · | $779 | -22.1% |
| 3 years | $34.01 | +21.3% | · | $1,213 | +21.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GPCR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.